AVALO THERAPEUTICS INC (AVTX)
Health Care · Immunology / Monoclonal Antibody Therapeutics · NASDAQ
Clinical-stage biotech developing abdakibart, a humanized anti-IL-1β antibody for hidradenitis suppurativa with Phase 2 data readout expected mid-2026.
What AVALO THERAPEUTICS INC does
Avalo Therapeutics is a clinical-stage biotechnology company focused on developing IL-1β-based treatments for immune-mediated inflammatory diseases. The company's lead product candidate, abdakibart (AVTX-009), is a humanized anti-IL-1β monoclonal antibody currently in Phase 2 clinical trials for hidradenitis suppurativa (HS), with topline data expected in Q2 2026. The company is preparing for pivotal Phase 3 trials and exploring additional indications for its lead asset.
Themes: ["IL-1β inhibition / inflammatory diseases","Hidradenitis suppurativa (HS) treatment","Monoclonal antibodies / biologics","Immunology / autoimmune disorders"]
Fundamentals
- Price$19.95 as of 2026-07-09 close
- Market cap$1.0B as of 2026-07-10
- 1-year return+303.0% as of 2026-07-09 close
- Net margin-23254.2% as of 2026-07-10
- Gross margin+242.2% as of 2026-07-10
- ROE-77.8% as of 2026-07-10
- Debt / equity0.03 as of 2026-07-10
- Revenue growth (YoY)-86.6% as of 2026-07-10
- Revenue CAGR (3y)-85.2% SEC XBRL
- Beta0.75 as of 2026-07-10
Key risks (from latest filing)
["Clinical development risk: Phase 2 LOTUS trial topline data readout in Q2 2026 is critical; failure to meet efficacy endpoints or safety concerns could derail the program and significantly impact company valuation.","Competition from established biologics: Currently approved HS treatments (adalimumab, secukinumab, bimekizumab) already achieve HiSCR50 in approximately 50% of patients, and the company must demonstrate superior efficacy or durability to compete.","Limited cash position and high cash burn: The company has a net cash position of approximately $82 million (cash + short-term investments of $82 million) as of Q1 2026 with R&D expenses of $14 million per quarter; runway and ability to fund pivotal trials and commercial operations remain uncertain."]
Competitors & peers
- AbbVie (ABBV) - adalimumab (TNF-α inhibitor for HS)
- Novartis (NVS) - ILARIS (canakinumab, IL-1β blocker)
- Novartis (NVS) - secukinumab (anti-IL-17A for HS)
- UCB (UCB) - bimekizumab (dual anti-IL-17A/F for HS)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.